BACKGROUND: The aim of this study was to report the clinical outcome and toxicity of radiochemotherapy in locally advanced gastric cancer (LAGC) patients treated according to the Intergroup 116 trial protocol in our institution. METHODS: We retrospectively reviewed 105 patients with LAGC treated with radical surgery and adjuvant radiochemotherapy. We analyzed overall survival (OS), disease-free survival (DFS), locoregional failure-free survival (LFS), prognostic factors and toxicity. RESULTS: The mean follow-up was 96.48 months. The majority of tumors were T3-T4 (75%) and 86.6% had nodal metastases. The OS, DFS and LFS rates to 3 years were 53.48%, 52.75% and 81.65%, respectively and to 5 years 40%, 46.73% and 76.77% respectively. The univariate analysis showed that N stage < N2, TN stage < IIIA, R0 resection and N‑ratio < 3 were statistically significant prognostic factors for OS and DFS, T stage < T4 for OS and N‑ratio < 3 for LFS. The group with D2 lymphadenectomy had worse LFS than the D1 group (65.2% vs 88.1%, respectively, p = 0.039) probably due to a significant difference in the proportion node positive patients in the D2 group (94% vs. 78%; p = 0.027). In the multivariate analysis, only R0 resection was statistically significant factor for improved OS (p = 0.018). Acute grade III-IV gastrointestinal and hematologic toxicity rates were 8.5% and 15.2%, respectively and 89.5% completed treatment as planned. CONCLUSION: Our results are consistent with those of the Intergroup-0116 trial for LAGC in terms of survival. This regimen is well tolerated and with acceptable toxicity. An R0 resection was an independent prognostic factor for improved OS.
BACKGROUND: The aim of this study was to report the clinical outcome and toxicity of radiochemotherapy in locally advanced gastric cancer (LAGC) patients treated according to the Intergroup 116 trial protocol in our institution. METHODS: We retrospectively reviewed 105 patients with LAGC treated with radical surgery and adjuvant radiochemotherapy. We analyzed overall survival (OS), disease-free survival (DFS), locoregional failure-free survival (LFS), prognostic factors and toxicity. RESULTS: The mean follow-up was 96.48 months. The majority of tumors were T3-T4 (75%) and 86.6% had nodal metastases. The OS, DFS and LFS rates to 3 years were 53.48%, 52.75% and 81.65%, respectively and to 5 years 40%, 46.73% and 76.77% respectively. The univariate analysis showed that N stage < N2, TN stage < IIIA, R0 resection and N‑ratio < 3 were statistically significant prognostic factors for OS and DFS, T stage < T4 for OS and N‑ratio < 3 for LFS. The group with D2 lymphadenectomy had worse LFS than the D1 group (65.2% vs 88.1%, respectively, p = 0.039) probably due to a significant difference in the proportion node positive patients in the D2 group (94% vs. 78%; p = 0.027). In the multivariate analysis, only R0 resection was statistically significant factor for improved OS (p = 0.018). Acute grade III-IV gastrointestinal and hematologic toxicity rates were 8.5% and 15.2%, respectively and 89.5% completed treatment as planned. CONCLUSION: Our results are consistent with those of the Intergroup-0116 trial for LAGC in terms of survival. This regimen is well tolerated and with acceptable toxicity. An R0 resection was an independent prognostic factor for improved OS.
Authors: Trevor Leong; Daryl Lim Joon; David Willis; Jayasingham Jayamoham; Nigel Spry; Jennifer Harvey; Juliana Di Iulio; Alvin Milner; G Bruce Mann; Michael Michael Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-14 Impact factor: 7.038
Authors: F J F Coimbra; W L Costa; A L Montagnini; A L Diniz; H S C Ribeiro; M J B Silva; M F S Begnami Journal: Eur J Surg Oncol Date: 2010-11-27 Impact factor: 4.424
Authors: Se Hoon Park; Tae Sung Sohn; Jeeyun Lee; Do Hoon Lim; Min Eui Hong; Kyoung-Mee Kim; Insuk Sohn; Sin Ho Jung; Min Gew Choi; Jun Ho Lee; Jae Moon Bae; Sung Kim; Seung Tae Kim; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: Stephen R Smalley; Leonard Gunderson; Joel Tepper; James A Martenson; Bruce Minsky; Christopher Willett; Tyvin Rich Journal: Int J Radiat Oncol Biol Phys Date: 2002-02-01 Impact factor: 7.038
Authors: K Kumagai; I Rouvelas; J A Tsai; D Mariosa; P A Lind; M Lindblad; W Ye; L Lundell; C Schuhmacher; M Mauer; B H Burmeister; J M Thomas; M Stahl; M Nilsson Journal: Eur J Surg Oncol Date: 2014-11-27 Impact factor: 4.424
Authors: Trevor Leong; B Mark Smithers; Michael Michael; Val Gebski; Alex Boussioutas; Danielle Miller; John Simes; John Zalcberg; Karin Haustermans; Florian Lordick; Christoph Schuhmacher; Carol Swallow; Gail Darling; Rebecca Wong Journal: BMC Cancer Date: 2015-07-21 Impact factor: 4.430
Authors: Fernando Mingol; Javier Gallego; Albina Orduña; Amparo Martinez-Blasco; Javier Sola-Vera; Pedro Moya; Miguel Angel Morcillo; Juan Antonio Ruiz; Rafael Calpena; Francisco-Javier Lacueva Journal: BMC Surg Date: 2015-05-22 Impact factor: 2.102